Biosimilar Dupilumab

About Sandoz

Sandoz, spun off from Novartis in October 2023, is a global champion in the off-patent pharmaceuticals market, dedicated to its social mission of expanding access to medicine. It achieves this through a dual-pillar strategy: a broad portfolio of generic drugs and a rapidly growing, scientifically advanced biosimilars franchise. As an independent public entity, Sandoz is now positioned to accelerate growth, optimize its capital structure, and directly capitalize on the significant long-term tailwinds in both the generics and biosimilars sectors worldwide.

Therapeutic Areas